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Background: Antibodies to glutamic acid decarboxylase (GAD ab) have been found in
patients with limbic encephalitis (LE) and chronic pharmacoresistant focal epilepsy (FE).
The objectives of the study were to: (1) analyze the clinical and neuroimaging course of
patients with FE+GAD ab, (2) compare these characteristics with a control group, and
(3) describe the most affected cerebral areas with structural and functional imaging.
Methods: Patients with FE + high titers of GAD ab and a follow-up of at least 5 years
were selected. Titers of serum GAD ab exceeding 2,000 UI/ml were considered high.
Evolutive clinical and radiological characteristics were studied in comparison to two
different control groups: patients with bilateral or with unilateral mesial temporal sclerosis
(BMTS or UMTS) of a non-autoimmune origin.
Results: A group of 13 patients and 17 controls were included (8 BMTS, 9 UMTS).
The most frequent focal aware seizures (FAS) reported by patients were psychic (5/13:
33%). Somatosensorial, motor, and visual FAS (4/13:32%) (p: 0.045), musicogenic
reflex seizures (MRS), and a previous history of cardiac syncope were reported only
patients (2/13:16% each) (p: NS). Comparing EEG characteristics between patients
and controls, a more widespread distribution of interictal epileptiform discharges (IED)
was observed in FE+ GAD ab patients than in controls (p:0.01). Rhythmic delta activity
was observed in all controls in anterior temporal lobes while in patients this was less
frequent (p: 0.001). No IED, even in 24 h cVEEG, was seen in 6 patients (46%).First
MRI was normal in 4/5 (75%) patients. During the follow-up mesial temporal lobe (MTsL)
sclerosis was observed in 5/8 (62%) of patients. All patients had abnormal FDG-PET
study. MTL hypometabolism was observed in 10/11 (91%) patients, being bilateral in
7/11 (63%). In controls, this was observed in 16/17 (94%), and it was bilateral in 8/17
(47%) (p: NS). Insular hypometabolism was observed in 5/11 (45%) patients (P:0.002).
Falip et al. Cortical Affected Areas in Epilepsy+GAD
Conclusions: Clinical, EEG, and FDG-PET findings in FE+GAD ab suggest a
widespread disease not restricted to the temporal lobe. Progressive MTL sclerosis
may be observed during follow-up. In comparison to what is found in patients
with non-autoimmune MTL epilepsy, insular hypometabolism is observed only in patients
with GAD ab, so it may be an important diagnostic clue.
Keywords: temporal lobe epilepsy, glutamic acid decarboxylase antibodies, autoimmune epilepsy, limbic system,
insula, hippocampus
INTRODUCTION
Gamma-aminobutyric acid (GABA) is the main inhibitor
neurotransmitter in the mature brain. GABAergic interneurons
represent 10–20% of neurons in the cortex and they play a
critical role in modulating the output of the critical excitatory
pyramidal neurons. Several groups of non-pyramidal GABAergic
cells have been identified. Parvalbumin (PV)-expressing, fast-
spiking basket cells form the most numerous class of cortical
interneurons, whose perisomatic, basket-shaped axonal boutons
exert exquisite control over the spiking activity of connected
neurons (1).
Antibodies against GAD, the rate-limiting enzyme for the
synthesis of GABA, were initially recognized in the serum and
cerebrospinal fluid (CSF) of patients with stiff person syndrome
(SPS), a rare central nervous system (CNS) disorder which
produces rigidity, and cramps frequently associated with other
autoimmune diseases, mainly type 1 diabetes mellitus (T1DM).
Moreover, GAD ab is identified in about 80% of newly diagnosed
T1DM patients, although at low titers compared with those
found in SPS. Since then, high levels of GAD ab have also been
described in several neurological disorders (2). Among patients
with epilepsy, GAD ab has been found not only in patients
with limbic encephalitis (LE) but also in patients with chronic
temporal lobe epilepsy (TLE) (3). A case report has suggested
that GAD ab can also produce epileptogenic areas outside the
temporal lobe, in particular in the inferior rolandic area (4). In
patients with acute debut presenting as LE, brain MRI usually
shows signal and volume changes, bilaterally in most cases, in
the temporolimbic structures. Chronic cases referred for epilepsy
surgery are frequently rejected because of bilateral independent
seizure onset zones in both temporal lobes (5).
One study using quantitative FLAIR analysis has suggested
that the amygdala is more affected than the hippocampus in
patients suffering LE of different etiologies including those
related to GAD ab (6). Interestingly, in patients with LE due
to GAD ab, MRI with voxel based morphometry performed 2
years after the onset of epilepsy showed no hippocampal volume
reduction (7). A case report has also observed no hippocampal
volume loss even 7 years after epilepsy debut (8).
In general there is little information about the long-term
clinical and radiological outcome of patients with epilepsy
+GAD ab. In addition, information about the cerebral areas
which are more involved is also scarce, and it is not known
whether the condition affects temporolimbic areas only or more
widespread regions.
The aims of our study were to: (1) analyze both clinical
and neuroimaging (structural and functional) characteristics of
patients with focal epilepsy (FE)+ GAD ab at epilepsy onset and
during follow-up, (2) compare these characteristics with those of
a control group of clinically similar patients without antibodies,




All patients with FE and high titers of GAD ab diagnosed at the
Hospital Universitari de Bellvitge from May, 2006, to December,
2015, were selected. Only patients with a disease duration (from
epilepsy onset) of more than 5 years were included in the study,
in order to provide an adequate overview of the evolution of the
disease.
In order to evaluate specific cerebral areas affected by GAD
ab, FDG-PET studies performed in patients were compared
with those from two different control groups: (1) a group of
patients with unilateral mesial temporal lobe sclerosis (MTS)
considered good surgical candidates after a congruent study
with scalp video-EEG, surgically treated and seizure free after
at least 1 year of follow-up but also undergoing an FDG-
PET, and (2) a group of patients with bilateral MTS of
known origin, provided that it was not autoimmune. The
last group included all the patients controlled in Hospital
de Bellvitge with bilateral MTS excluding patients with an
autoimmune origin. Seizure classification was made according
to the ILAE 2017 operational classification of seizure types
(9).
Comorbid pathologies were divided into three categories:
autoimmune, neurological, and psychiatric. Comorbid
autoimmune diseases considered were the group of 12
autoimmune diseases that appear most frequently in epilepsy
according to the population study of Ong et al. (10). The
comorbid psychiatric diseases considered were mood and
anxiety disorders, attention deficit hyperactivity disorder, and
psychosis according to Kanner (11). Neurological comorbid
pathologies considered were the rest of the neurological
pathologies, apart from memory disturbances, that are produced
by the same etiology that also produced the epilepsy.
The study was approved by the Ethical Committee of Bellvitge
University Hospital. Informed consent was obtained from all
patients.
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MATERIAL
MRI
MRI scans were acquired using a Philips 1.5 or 3 Tesla MRI
scanner (Intera, Philips Medical Systems, Amsterdam, The
Netherlands) according to a standard epilepsy protocol (12).
Follow-up MRI studies were done with a 3 Tesla scanner while
most of the first studies had been done with a 1.5 Tesla scanner.
Fluodeoxiglucose (FDG) PET Studies
Following FDG injection and uptake under euglycemic
(overnight fasting) and standardized resting conditions (eyes
open, reduced ambient noise), FDG-PET scans were acquired
on a Gemini TF 64 PET/CT scanner (Philips, The Netherlands;
n = 9; 10min 3D acquisition starting 50min p.i. of 280 ± 62
MBq FDG). Visual readings were performed after automatic
anterior-posterior commissure line realignment on transaxial,
coronal, and sagittal slices spanning the entire brain.
FDG-PET/MRI Studies
After PET and MRI were carried out, images from the two
techniques were normalized so they could be superimposed
on each other with anatomical reliability, and were then co-
recorded.
Cerebral MRI and FDG-PET scans were analyzed by a
neurologist (JS or MF) independently of the neuroradiologist
(SC), and by a nuclear medicine specialist (LR). The
neuroradiologist and the nuclear medicine specialist were
blinded to clinical characteristics and autoantibody status. The
results from the two groups were compared and in case of
discrepancies in a particular study, this was analyzed together
and a consensus was obtained.
GAD Antibodies Determination
GAD ab was analyzed in serum and CSF (when available) with
enzyme-linked immunosorbent assay (ELISA) at the Hospital
de Bellvitge. All patients with focal epilepsy of unknown
origin are tested for GAD ab in blood serum (20–30 patients
per year). Patients with acute onset are tested for GAD also
in CSF. In order to confirm the results in patients with
positive GAD ab, immunohistochemistry and radioimmunoassay
(RIA) were performed at Hospital Clinic of Barcelona, as
described elsewhere (13). Additional immunological studies
were performed, including determination in serum and CSF
of onco-neuronal antibodies (Hu, Yo, Ma, Tr, amphiphysin)
and antibodies against neuronal surface antigens (NSA-abs).
These studies were carried out in the Neuroimmunology Unit
of the Hospital Clinic of Barcelona. NSA-abs were identified by
immunocyto-chemistry of rat hippocampal neuronal cultures, as
described elsewhere (14).
Serum titers of GAD ab were defined as high when in excess
of 2,000 IU/ml. High titers are required to consider the antibody
as possibly pathogenic in the neurological symptoms (15, 16). In
pharmacoresistant patients several determinations were made, in
some cases before and after different immunotherapies (follow-
up determinations were made at the Hospital de Bellvitge using
ELISA) and results were given as exact number if titers were
below 2,000 UI or >2,000 UI without specifying the exact value.
Neuropsychological Examination
A comprehensive neuropsychological examination was
performed, including intelligence and memory tests. We
included certain subtests (Logical Memory and Visual
Reproduction) of the Wechsler Memory Scales (WMS,
WMS-R, and WMS-III). Premorbid intelligence was tested
with the Vocabulary subtest of the Wechsler Adult Intelligence
Scales (WAIS and WAIS-III). For statistical analysis of
neuropsychological variables, normalized “z” scores were
computed using mean and standard deviations of the raw scores
of the general population. Verbal and visual memory scores were
compared with vocabulary scores individually. We consider
the subjects as memory-impaired if more than one subtest “z”
score was one standard deviation (SD) below the general level
of intelligence (vocabulary), as proposed by Lezak (17). Memory
impairment was divided into mild, moderate, or severe. Severe
memory deficit was considered when subject score was below 2.5
SD and moderate between 1.5 and 2.5 SD.
Statistical Analysis
All statistical analysis was performed using SPSS for Windows
(version 22.0, SPSS Inc., Chicago, IL, U.S.A.). Categorical
variables were analyzed using a one-tailed chi-square analysis
(with Yates correction when warranted), and continuous data
were analyzed using t-test or Mann-Whitney U-test, ANOVA,
and Kruskal-Wallis test for non-parametrical analysis. All tests
were two-tailed; P-values < 0.05 were considered significant.
RESULTS
We identified 22 patients with epilepsy and GAD ab in the
Epilepsy Unit database of the Hospital Universitari de Bellvitge.
From this group we selected patients with high serum titers of
GAD ab (>2,000 UI/ml) and a follow-up of more than 5 years.
The excluded patients were 1 patient with generalized epilepsy, 2
who died during follow-up, 1 with status epilepticus, and 1 with
pneumonia. Another patient was lost to follow-up. Finally, 13
patients with epilepsy and high titers of GAD ab were included.
Among these only 2/13 (15%) patients referred an acute debut,
one with limbic encephalitis that occurred during pregnancy
(together with eclampsia and Hellp syndrome) and the other
with an occipital status epilepticus in the context of celiac disease.
The rest of the patients debuted with focal epilepsy. GAD ab in
CSF was analyzed in 6/13 (46%) patients and was positive in
all. Intrathecal synthesis was observed in 5/6 (83%). During the
follow-up, several serum GAD determinations were obtained in
the patients with pharmacoresistant epilepsy, and at least two
determinations were obtained in all patients. The results were
always above 2,000 UI/ml. No other onco-neuronal antibodies
or antibodies against neuronal surface antigens (NSA-abs) were
identified.
Control patients were selected from the same database. Eight
patients had bilateral mesial temporal lobe sclerosis (BMTS):
2 due to meningitis, 1 to measles encephalitis, 3 to connatal
anoxia, 1 encephalitis from human immunodeficiency virus, and
1 encephalitis due to parvovirus B19. Nine patients had unilateral
MTS: 7 had suffered febrile seizures and 2 did not report initial
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precipitating injury. Asmentioned above, all UMTSwere seizure-
free after a temporal lobectomy. In all the control patients an
immunological battery including GAD ab was performed and
was negative in all cases.
Demographic and clinical characteristics of patients and
controls are presented in Table 1.
No differences were observed between patients and controls
in terms of gender and age. Patients reported earlier epilepsy
onset compared to controls (p: 0.004), both UMTS and
BMTS, and with a shorter disease duration (p: 0.005). After
a mean disease duration of 14 years (range 6–53 years),
nearly half of the patients with FE +GAD ab−6/13 (46%)—
were seizure-free. Interestingly only one of the patients who
was seizure-free received immunosuppressive agents, due to
a liver transplant. Half of the patients with drug-resistant
FE+ GAD ab had received immunotherapy (corticoids, IVIG,
azathioprine, cyclophosphamide, or mycophenolate) without
significant improvement in seizure frequency. All control
patients with UMTS were seizure-free after surgery while none
of those with BMTS were. BMTS patients suffered weekly or
monthly seizures.
In comparing the seizure characteristics of FE+ GAD
ab patients with those of controls (BMTS or UMTS) some
differences were found: somatosensorial, motor, and visual focal
aware seizures were only reported by patients with FE +GAD
ab (4/13: 30%, p:0.045), suggesting a symptomatogenic zone
beyond the temporal lobe. In addition, some patients reported
different seizure types during the disease evolution. Oneman had
seizures with cephalic parestesias and right focal motor clonic
seizures during the first months of the disease. This seizure type
completely disappeared and afterwards he started to present a
déjà-vu sensation preceding a focal impaired awareness seizure.
Another man reported visual focal aware seizures only at disease
onset while later on this seizure type completely disappeared.
Considering seizure types, focal to bilateral tonic-clonic seizures
(FBTCS) as the main seizure type were only reported by patients
with FE + GAD ab, and they occurred predominantly during
night sleep. On the other hand, focal impaired awareness seizures
(FIAS) were the predominant seizure type in controls (BMTS
and UMTS) (p: 0.025). Two patients with FE +GAD ab reported
musicogenic reflex seizures in addition to non-provoked FIAS
and FBTCS. None of the controls mentioned any kind of reflex
seizures (p: NS).
Apart from seizures, a previous history of syncope was
reported in 2/13 (16%) of the patients with FE +GAD ab.
None of them had a history of cardiac disorders. One of the
patients, a man aged 83, was diagnosed at 70 with carotid sinus
hypersensitivity and a pacemaker was implanted. He suffered no
more syncopes but 2 years later he started suffering FIAS. Now on
antiepileptic drugs (lamotrigine 300 mgr/day), his seizures have
been completely controlled although he suffers from progressive
verbal memory loss.
Comparing EEG characteristics of patients and controls,
a more widespread distribution on interictal epileptiform
discharges (IED) was observed in FE+ GAD ab patients than
in controls, predominantly in the frontopolar and frontocentral
regions, but also in the occipital and parietal regions (p:0.01).
Rhythmic delta activity was observed in all controls in anterior
temporal lobes (affecting one or both) while in patients this was
less frequent (p: 0.001) and appeared in anterior temporal lobe
areas and in frontal lobe areas (in two patients only in frontal
lobe areas). Six patients (46%) had no IED even in prolonged
VEEG study. Ictal EEG was obtained in all controls and in
three FE+GAD ab patients. In 2/3 patients it was suggestive
of unilateral temporal anterior seizures while in 1/3 bilateral
independent anterior temporal lobe seizures were recorded.
Memory impairment was observed in 8/13 (61%) of the
patients with FE+ GAD ab; it was moderate in three
patients. Interestingly, in three of the 8 patients seizures
were completely controlled. Memory decline over the last 8
years was documented in 4/8 (50%) FE+GAD ab patients.
All 8/8 (100%) control patients with BMTS had moderate
or severe memory impairment, both verbal and visual, with
other neuropsychological deficits mostly affecting frontal lobe
structures. Control patients with UMTS had mild or moderate
verbal or visual memory impairment, with mild or moderate
verbal memory impairment in 3/9 (33%), mild ormoderate visual
memory impairment in 4/9 (44%), andmild ormoderate bilateral
memory impairment in 2/9 (22%).
Comparing comorbidities, patients with FE+GAD ab tended
to suffer other autoimmune diseases (T1DM being the most
frequent) (p: 0.001) while patients with BMTS or UMTS tended
to suffer more psychiatric comorbidities although this last
difference was not statistically significant.
MRI Characteristics (see Table 2, Figures 1,
2)
In 5 (38%) FE+GAD ab patients the first available MRI
was performed within the first year from the epilepsy debut.
In one patient (1/5; 20%) the initial MRI, done in the
first 3 months, showed bilateral amygdalar and hippocampal
hyperintensities without atrophy. Greater hyperintensities were
found in amygdalar tissue compared with hippocampus (patient
previously reported) (3). In the rest (4/5; 80%) the first MRI was
normal.
A follow-up MRI was performed in all patients. In 8 (61%)
FE+GAD ab patients several (>3) MRI studies were done. The
patient with bilateral amygdalar-hippocampal hyperintensities
but no atrophy, when scanned 11 years later, had a normal MRI
without hippocampal atrophy. Subtle unilateral hippocampal
sclerosis (predominantly affecting the hippocampal tail) was
found in 4 (80%) patients with an initially normal MRI. Three
of them had a disease duration of between 5 and 10 years and the
other a disease duration >30 years.
In a patient whose first available MRI was done 11 years
after disease onset, left hippocampal sclerosis was observed.
Thirteen years later the patient suffered an acute episode of limbic
encephalitis (probably a relapse) affecting the right hippocampus
and evolving to a bilateral MTS within a year.
In only three controls was an initial MRI available (carried out
within the first year from epilepsy debut). In two, both suffering
encephalitis, bilateral hippocampal/amygdalar hyperintensities
were found, while in the other initial MRI was normal.
In all, after <3 months bilateral hippocampal atrophy was
observed.
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TABLE 1 | Patients and controls.
PATIENTS CONTROLS p
FE+ GAD ab 13 BMTS 8 UMTS 9
YEARS (RANGE) YEARS (RANGE) YEARS (RANGE)
Age 51 (24–83) 52(39–66) 46(29–68) NS
Age at epilepsy onset 36(11–72) 16.(2–45) 14(1–34) 0.004
Disease duration 14 (5–53) 35(18–55) 32 (8–49) 0.005
NUMBER (%) NUMBER (%) NUMBER (%)
Gender: Male 6 (46) 4 (57) 5 (55) NS
FOCAL AWARENESS
No awareness 5 (33) 6 (75) 0 (0) 0.045
Psychic 5 (33) 1 (14) 3 (33)
Epigastric 1 (8) 0 (0) 4 (44)
Taste/olfactory 0 (0) 1 (14) 0 (0)
Somatosensorial 1 (8) 0 (0) 0 (0)
Visual 2 (16) 0 (0) 0 (0)
Autonomic 0 (0) 0 (0) 1 (11)
Motor 1 (8) 0 (0) 0 (0)
Musicogenic reflex seizures 2 (15) 0 (0) 0 (0) NS
Seizure type (main) 0.025
FIAS 8 (61) 8 (100) 9 (100)
FBTCS 5 (41) 0 (0) 0 (0)
Prior history of syncopes 2 (16) 0 (0) 0 (0) NS
Acute onset or acute relapses* 3 (23) 5 (62) 0 (0) NS
Seizure-free (>1 year) 6 (46) 0 (0) 0 (0)** 0.003
Memory impairment 6 (46) 8 (100) 9 (100) NS
Bilateral 1 (10) 8 (100) 2 (22)
Dominant 4 (30) 0 (0) 3(33)
Non-dominant 0 (0) 0 (0) 4 (44)
Autoimmune comorbidities*** 11 (85) 0 (0) 0 (0) 0.001
Psychiatric comorbidities 0 (0) 4 (50) 1 (11) NS
Interictal psychosis 0 (0) 2 (24) 0 (0)
Anxiety disorders 0 (0) 1 (12) 1 (1)
Mood disorders 0 (0) 1 (12) 0 (0)
Other neurological comorbidities 1 (8) 2 (12) 0 (0) NS
Mental retardation 0 (0) 1 (12) 0 (0)
Nistagmus 1 (8) 0 (0) 0 (0)
Mitochondrial SFN 0 (0) 0 (0) 0 (0)
Tumor ADK colorectal/prostatic or hepatic 3(25) 1 (12) 0 (0) NS
EEG (SLOW ACTIVITY)
TIRDA 4 (30) 8 (100) 9 (100) 0.001
FIRDA 3 (23) 0 (0) 0 (0) NS
EEG, IED
Unilateral 3 (23) 3 (37) 9 (100) NS
Temporal (>80%) 1 (8) 5 (62) 9 (100) NS
Bilateral temporal 7 (53) 4 (50) 0 (0) NS
Extratemporal 5 (33) 1 (12) 0 (0) 0.01
Absence of IED 6 (46) 0 (0) 0 (0) 0.003
Electroclinical and demographic characteristics. FE+GAD ab: focal epilepsy with glutamic acid decarboxylase antibodies, BMTS: bilateral mesial temporal lobe sclerosis, UMTS:
unilateral mesial temporal lobe sclerosis. FIAS: focal impaired awareness seizure, FBTCS: focal to bilateral tonic-clonic seizure. LE: limbic encephalitis. Autoinmune diseases reported:
DM1, Hypothyroidism, psoriasis, celiac disease and myasthenia. ADK: adenocarcinoma. SFN: small fiber neuropathy. EEG: electroencephalogram. TIRDA: temporal rhythmic delta
activity. FIRDA: frontal rhythmic delta activity, IED: interictal epileptiform discharges. *Considered acute onset: Status epilepticus, limbic encephalitis or viral or bacterial encephalitis or
meningitis. **Prior to epilepsy surgery. ***One or more autoimmune diseases per patient.
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FIGURE 1 | Patient with pharmacoresistant temporal lobe epilepsy from age 25. Five years later suffers weekly focal impaired awareness seizures but no memory
decline. Left hippocampal tail atrophy is found on 2012 MRI and confirmed in 2015 (Coronal T1).
FDG- PET Characteristics (see Tables 2, 3
and Figure 3)
Initial FDG-PET was available in 2 patients because both
experienced an acute disease onset or had a relapse. In both
cases unilateral temporal lobe hypermetabolism was observed. In
one patient the hypermetabolism persisted for 6 months despite
immunosuppression therapy (corticoids, IVIG, and monthly
cyclophosphamide).
A follow up FDG-PET was done in 11/13 (84.6%) patients
more than 5 years after epilepsy debut. In 2 patients more than
one FDG-PET studies was performed.
All patients had an abnormal FDG-PET study. Mesial
temporal lobe hypometabolism was observed in 10/11 (91%)
patients; it was bilateral in 8 (72%) and unilateral in 3
(27%). Moreover, insular hypometabolism was observed in 5/11
(45%) patients; it was bilateral in 3 (27%). In all patients
except one, insular hypometabolism was observed together with
mesial temporal lobe hypometabolism. Isolated unilateral insular
hypometabolism was observed in one patient—a man with
somatosensorial focal awareness and normal MRI.
Comparing FDG-PET Findings to MRI
Findings in Patients (see Table 3)
At the end of follow-up 5 patients had a normal MRI (without
hippocampal atrophy) but none of them had a normal FDG-PET.
Among 5 FE+GAD ab patients who went on to show unilateral
hippocampal atrophy, 3 (60%) had ipsilateral hippocampal
hypometabolism and 2 (40%) bilateral hippocampal
hypometabolism, with associated insular hypometabolism
in one. Interestingly, 2 FE+GAD ab patients (27%) with a
normal MRI showed bilateral hippocampal hypometabolism,
which was associated with insular hypometabolism in one.
The patients with bilateral hippocampal sclerosis also had
bilateral hippocampal hypometabolism and bilateral insular
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FIGURE 2 | Patient with epilepsy debut at 56. Nowadays seizure-free but with progressive memory decline. (A) First available MRI shows left hippocampal atrophy
and hyperintensity (coronal flair). (B) Three years later bilateral hippocampal hyperintensities are observed without right hippocampal atrophy (coronal flair). (C) Three
years later nodular right hippocampal contrast enhancement is observed (coronal T1 after injection of gadolinium). (D) After 6 months bilateral hippocampal sclerosis
(atrophy+ hyperintensity) is observed (coronal flair).
hypometabolism. Overall, only 3 patients (27%) had strictly
unilateral mesial temporal involvement (considering FDG-PET
and MRI findings).
Comparing FDG- PET Findings of FE +
GAD ab Patients and Controls (see
Figure 3)
FDG-PET was performed in 7/8 (88%) BMTS controls and
in 9/9 (100%) UMTS controls. Bilateral mesial temporal lobe
hypometabolism was observed in all BMTS controls, and
unilateral or bilateral mesial temporal lobe hypometabolism in
all UMTS patients, whereas insular hypometabolism was not
observed in any (p: 0.002).
DISCUSSION
In our study both clinical and paraclinical findings suggest that
FE +GAD ab involves limbic areas but also the insular region,
and in one patient this lobe was the only one involved.
Clinical symptoms suggestive of insular epilepsy include
occurrence in full consciousness of a symptomatic sequence
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TABLE 3 | Correlation between MRI findings and FDG-PET findings in patients













2 (18%) 1 (9%)





2 (18%) 1 (9%)
HIP, Hippocampal, MRI, magnetic resonance imaging, FDG-PET, fluoxideoxiglucose
positron emission tomography.
associating laryngeal discomfort with thoracic oppression or
dyspnoea, unpleasant paraesthesia—a warm sensation focused
on the perioral region or extending to a large somatic territory,
and dysarthria, or dysphonic, speech defects (18). One of the
patients reported seizures as an unpleasant paresthesia starting
in his left arm and rapidly affecting face and tongue, with the
left half of his body always in full awareness. A very specific
form of sensitive focal aware seizures (pilomotor seizures) have
been reported in patients with limbic encephalitis. These are
probably also suggestive of insular involvement (19). Two recent
case series have also suggested that insular semiology (especially
other autonomic semiology) is a part of pilomotor seizures,
while perisylvian semiology is highly suggestive of autoimmune
epilepsy related to GAD ab or to other antibodies (20–22).
Bradyarrhythmia has recently been described as a distinctive
prodrome of voltage-gated potassium channel complex/leucine-
rich glioma inactivated 1 antibody encephalitis (VGKC/LGI1–ab)
leading to pacemaker implantation in 3 cases (23), just as in one
of our patients.
The insular region is considered to be one of the cortical
autonomic areas (24). GABAergic neurons have been found in
several brain regions involved in the control of cardiorespiratory
function (25) including the nucleus tractus solitarius (NTS) (26)
and the ventrolateral medulla (27). GABA is known to play a
vital role in several pacemaker networks. The most extensively
studied pacemaker network is in the suprachiasmatic nucleus
of the hypothalamus, an area that is responsible for controlling
food intake and sleep as well as regulating body temperature and
heart rate (28). We hypothesize that a loss of GABAergic neurons
due to GAD ab, especially in certain autonomic brain areas
(hypothalamus, insula), could affect the modulation of heart rate.
Functional neuroimaging studies also support the hypothesis
of an insular involvement in patients with FE+GAD ab. In most
of our patients FDG-PET showed hypometabolism in MTLE
structures, but also insular hypometabolism in nearly 40% of
patients. No insular hypometabolism was found in controls.
Another case report showed abnormal extratemporal glucose
metabolism (in this case hypermetabolism) in a patient with
FE+ GAD ab (29). FDG-PET scans have been demonstrated
to reliably lateralize seizure focus in MTLE, with decreased
glucose uptake in the epileptogenic temporal lobe (30). It
is generally believed that the region of hypometabolism is
larger than the epileptogenic zone, and some studies (31)
have suggested that insular hypometabolism, most frequently
ipsilateral to the hippocampal sclerosis, is due to seizure
propagation and does not influence seizure outcome after
surgery. Other studies (32–34) have found a relationship between
extratemporal hypometabolism in MTLE patients (mainly insula
and frontal lobe) with poorer surgical outcome. Case studies
are nowadays suggesting that pharmacoresistant FE+ GAD ab
has a poor surgical outcome (35, 36). Bitemporal involvement
and extratemporal involvement (insular) could be an explanation
for this poor surgical outcome. In addition, insular involvement
could be an important diagnostic clue in patients with MTLE
epilepsy of unknown origin, by raising suspicion of an
autoimmune origin due to GAD ab.
In our group of patients with FE + GAD ab, two reported
suffering musicogenic reflex seizures (MRS) [Patients previously
published (37)]. MRSmay be a distinctive seizure type in patients
with epilepsy and GAD ab.
Little information is available about long-term follow-up of
patients with FE + GAD ab. In a recent study no hippocampal
sclerosis (HS) was observed during the follow-up in 12 patients;
however, only one of them was followed up for more than 5
years (35). In the study of Wagner et al. (6) no hippocampal
volume loss was observed after two years. In another recent study
which included 19 patients with FE+ GAD ab, hippocampal
abnormalities were found in <30% of patients (38). In our
study, where all patients were followed up for over 5 years and
in the case of 2 patients more than 30 years, slight unilateral
hippocampal atrophy was observed in nearly half of them and
bilateral hippocampal atrophy in one. The most important
finding in the study of Fredriksen et al. (38) was that patients
had a disproportionate parenchymal atrophy with age, again
suggesting a widespread disease not limited to the temporal lobe.
Interestingly, an anatomopathological study including 2
patients who underwent temporal lobectomy for medically
refractory epilepsy + GAD ab (9 and 10 years follow-up)
observed an ILAE type 3 HS or CA4 predominant HS, without
lymphocytes or plasma cell infiltration (39). ILAE type 3 HS
predominantly affects CA4 and the dentate gyrus. ILAE type 3
HS is the least common form of HS; patients with this form of
HS typically develop epilepsy at a later age, often in the absence
of an initial precipitating injury or identifiable etiology (40).
Three of our patients reported progressive memory decline
even when their epilepsy was well-controlled. Tagaki et al.
(41) conducted a case control study comparing cognitive
performance of late-onset type one diabetic (LADA) patients
with GAD ab and matched type 2 diabetes mellitus patients.
They observed that verbal and visual test scores were lower in
LADA+GAD ab patients and hypothesized that GAD-positive
diabetic patients had an increased risk of cognitive decline
compared to patients with type 2 diabetes of comparable diabetic
severity.
In addition, insular atrophy and an abnormal insula
functional network are also related to memory loss found in early
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FIGURE 3 | (A) Control patient who suffered measles encephalitis at 2. Epilepsy started at 8. Currently (more than 20 years later) suffers weekly seizures and severe
memory deficits. MRI shows bilateral hippocampal atrophy and FDG PET bilateral medial temporal lobe hypometabolism with normal insular metabolism. (B) Control
patient who suffered febrile seizures. Epilepsy started at 9. He suffered weekly FIAS preceded by non-specific sensation. MRI right hippocampal hyperintensity and
FDG-PET right mesial hypometabolism with normal insular metabolism. (C) Patient with T1DM from age 29 and temporal lobe epilepsy from age 30. MRI remains
normal after 5 years but FDG-PET shows bilateral medial temporal lobe hypometabolism and left insula hypometabolism. (D) Patient with epilepsy from age 56.
Seizure-free but progressive and severe memory decline. MRI shows bilateral hippocampal sclerosis and insular atrophy, and FDG-PET shows bitemporal medial
hypometabolism and bilateral insular hypometabolism.
stages of Alzheimer disease and can be a marker of progression
to Alzheimer disease in patients with mild amnestic cognitive
impairment (42). Both progressive insular and hippocampal
damage might account for the memory decline observed in our
patients.
CONCLUSIONS
Epilepsy with GAD ab affects the limbic system unilaterally
and, more frequently, bilaterally. Clinical, EEG, and FDG-PET
findings suggest a widespread disease not restricted to the
temporal lobe.
Progressive memory decline together with progressive
hippocampal damage may be observed even in patients with
well-controlled epilepsy.
Insular hypometabolism is only observed in epilepsy patients
with GAD ab and not in controls with unilateral or bilateral MTS,
so it may be an important diagnostic clue.
STUDY LIMITATIONS
Our study has some limitations, notably the low number of
patients included and the selection bias in forming the two
control groups. We included all patients with BMTS followed
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up in our center with sufficient information, and also those with
the “purest” UMTS. However, the most important limitations are
probably the lack of initial MRI studies in some patients andmost
of the controls, and the lack of follow-up studies in patients with
well-controlled epilepsy. Moreover, but no less important, the use
of different MRI scanners (the first studies were done with a 1.5T
scanner and the following studies with a 3T scanner) could have
led to an underestimation of mild hippocampal atrophies in the
first studies.
Larger studies with longer follow-up are needed to confirm
our initial findings.
AUTHOR CONTRIBUTIONS
MF and MC conceived and designed the study. MF, SJ,
CC, JM, and JB analyzed the data. SC, JS-P, LR-B, and
MF analyzed MRI, FDG-PET, and MRI/PET images. MF and
FM analyzed GAD determinations. MF and MC wrote the
paper.
FUNDING
This study was supported in part by a grant from the Spanish
National Institute of Health (PI10/00738).
ACKNOWLEDGMENTS
The authors thank all the patients for their collaboration. Thanks
also to Dr. Francesc Graus for performing the immunological
determinations at the Hospital Clinic. This study was supported
in part by a grant from the Spanish National Institute of Health
(PI10/00738). Thanks to the support of the Research Committee
of the Hospital Universitari de Bellvitge.
REFERENCES
1. Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C.
Interneurons of the neocortical inhibitory system. Nat Rev Neurosci. (2004)
5:793–80. doi: 10.1038/nrn1519
2. Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R,
et al. Spectrum of neurological syndromes associated with glutamic acid
decarboxylase antibodies: diagnostic clues for this association. Brain (2008)
131:2553–63. doi: 10.1093/brain/awn183
3. Falip M, Miro J, Carreño M., Saiz A, Villanueva V, Quilez A, et al.
Prevalence and immunological spectrum of temporal lobe epilepsy with
glutamic acid decarboxylase antibodies. Eur J Neurol. (2012) 19:827–33.
doi: 10.1111/j.1468-1331.2011.03609.x
4. Monnerat BZ, Rodrigues T, Nakano FN, Júnior AV,Martins AP, Sakamoto AC.
Opercular myoclonic-anarthric status epilepticus due to antibody-associated
encephalitis. Epileptic Disord. (2013) 15:342–6. doi: 10.1684/epd.2013.0596
5. Martin RC, Sawrie SM, Knowlton RC, Bilir E, Gilliam FG, Faught
E, et al. Bilateral hippocampal atrophy: consequences to verbal
memory following temporal lobectomy. Neurology (2001) 57:597–604.
doi: 10.1212/WNL.57.4.597
6. Wagner J, Schoene-Bake JC, Malter MP, Urbach H, Huppertz HJ, Elger
CE, et al. Quantitative FLAIR analysis indicates predominant affection of
the amygdala in antibody-associated limbic encephalitis. Epilepsia (2013)
54:1679–87. doi: 10.1111/epi.12320
7. Wagner J, Weber B, Elger C. Helmstaedter C, Malter MP, Stoecker W,
et al. Early and chronic grey matter and volume changes in limbic
encephalitis revealed by voxel-based morphometry. Epilepsia (2015) 56:754–
61. doi: 10.1111/epi.13297
8. Fauser S, Uttner I, Ariño H, Scherbaum A, Saiz A, Lewerenz J. Long latency
between GAD-antibody detection and development of limbic encephalitis – a
case report. BMC Neurol. (2015) 15:177–81. doi: 10.1186/s12883-015-0435-9
9. Fisher R., Cross H., D’Souza C., Higurashi N, Hirsch E, Jansen FE, et al.
Instruction manual for the ILAE 2017 operational classification of seizure
types. Epilepsia (2017) 58:531–42. doi: 10.1111/epi.13670
10. OngMS, Kohane IS, Cai T, GormanMP,Mandl KD. Population-level evidence
for an autoimmune etiology of epilepsy. JAMA Neurol. (2014) 71:569–74.
doi: 10.1001/jamaneurol.2014.188
11. Kanner A. Psychiatric comorbidities and epilepsy: is it the old story of the
chicken and the egg? Ann Neurol. (2012) 72:153–5. doi: 10.1002/ana.23679
12. Wellmer J, Quesada CM, Rothe L, Elger CE, Bien CG, Urbach H.
Proposal for a magnetic resonance imaging protocol for the detection of
epileptogenic lesions at early outpatient stages. Epilepsia (2013) 54:1977–87.
doi: 10.1111/epi.12375
13. Saiz A, Arpa J, Sagasta A, Casamitjana R, Zarranz JJ, Tolosa E, et al.
Autoantibodies to glutamic acid decarboxylase in three patients
with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus,
and polyendocrine autoimmunity. Neurology (1997) 49:1026–30.
doi: 10.1212/WNL.49.4.1026
14. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A,
Houghton DJ, et al. Treatment responsive limbic encephalitis identified
by neuropil antibodies: MRI and PET correlates. Brain (2005) 128:1764–77.
doi: 10.1093/brain/awh526
15. Peltola J, Kulmala P, Isojärvi J, Saiz K, Latvala J, Palmio K, et al. Autoantibodies
to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.
Neurology (2000) 55:46–50. doi: 10.1212/WNL.55.1.46
16. Giometto B, Nicolao P, Macucci M, Tavolato B, Foxon R, Bottazzo GF.
Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase
autoantibodies. Lancet (1998) 352:457. doi: 10.1016/S0140-6736(05)
79192-3
17. Lezak MD, Gray DK. Sampling problems and nonparametric solutions in
clinical neuropsychological research. J Clin Neuropsychol. (1984) 6:101–6.
doi: 10.1080/01688638408401200
18. Isnard J, Guénot M, Sindou M, Mauguiere F. Clinical manifestations of
insular lobe seizures: a stereo-electroencephalographic study. Epilepsia (2004)
45:1079–90. doi: 10.1111/j.0013-9580.2004.68903.x
19. Rocamora R, Becerra JL, Fossas P, Gomez M, Vivanco-Hidalgo RM, Mauri
JA, et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis?
Seizure (2014) 23:670–3. doi: 10.1016/j.seizure.2014.04.013
20. Gillinder L, Tjoa L, Mantzioris B, Blum S, Dionisio S. Refractory
chronic epilepsy associated with neuronal auto-antibodies: could
perisylvian semiology be a clue? Epileptic Disord. (2017) 19:439–49.
doi: 10.1684/epd.2017.0946
21. Baysal-Kirac L, Tuzun E, Erdag E, Ulusoy C, Vanli-Yavuz EN, Ekizoglu E,
et al. Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic
findings. J Neurol. (2016) 263:455–66. doi: 10.1007/s00415-015-8002-2
22. Najjar S, Pearlman D, Najjar A, Ghiasian V, Zagzag D, Devinsky O,
et al. Extralimbic autoimmune encephalitis associated with glutamic acid
decarboxylase antibodies: an underdiagnosed entity? Epilepsy Behav. (2011)
21:306–13. doi: 10.1016/j.yebeh.2011.03.038
23. Naasan G, Irani S, Bettcher B, Geschwind M, Gelfand J. Episodic
bradycardia as Neurocardiac prodrome to voltage-gated potassium channel
complex/leucine-rich glioma inactivated-1 antibody encephalitis. JAMA
Neurol. (2014) 71:1300–4. doi: 10.1001/jamaneurol.2014.1234
24. Samuels MA. The brain-heart connection. Circulation (2007) 116:77–84.
doi: 10.1161/CIRCULATIONAHA.106.678995
25. Dehkordi O, Millis RM, Dennis GC, Jazini E, Williams C, Hussain D,
et al. Expression of alpha-7 and alpha-4 nicotinic acetylcholine receptors by
GABAergic neurons of rostral ventral medulla and caudal pons. Brain Res.
(2007) 1185:95–102. doi: 10.1016/j.brainres.2007.09.027
26. Wang J, Irnaten M, Mendelowitz D. Characteristics of spontaneous and
evoked GABAergic synaptic currents in cardiac vagal neurons in rats. Brain
Res. (2001) 889:78–83. doi: 10.1016/S0006-8993(00)03112-7
Frontiers in Neurology | www.frontiersin.org 11 January 2019 | Volume 9 | Article 1143
Falip et al. Cortical Affected Areas in Epilepsy+GAD
27. Favero MT, Takakura AC, de Paula PM, Colombari E, Menani JV, Moreira
TS. Chemosensory control by commissural nucleus of the solitary tract in
rats. Respir Physiol Neurobiol. (2011) 179:227–34. doi: 10.1016/j.resp.2011.
08.010
28. Aton S, Huettner J, Straume M, Herzog ED. GABA and Gi/o differentially
control circadian rhythms and synchrony in clock neurons. Proc Natl Acad
Sci USA. (2006) 103:19188–93. doi: 10.1073/pnas.0607466103
29. Kojima G, Inaba M, Bruno MK. PET-positive extralimbic presentation of
anti-glutamic acid decarboxylase antibody-associated encephalitis. Epileptic
Disord. (2014) 16:358–61. doi: 10.1684/epd.2014.0666
30. Theodore WH, Newmark ME, Sato S, Brooks R, Patronas N, De La
Paz R, et al. 18F. Fluorodeoxyglucose positron emission tomography
in refractory complex partial seizures. Ann Neurol. (1983) 14:429–37.
doi: 10.1002/ana.410140406
31. Bouilleret V, Duphont S, Spelle L, Baulac M, Samson Y, Semah F.
Insular cortex involvement in mesiotemporal lobe epilepsy: a positron
emission tomography study. Ann Neurol. (2002) 51:202–8. doi: 10.1002/ana.
10087
32. Wong CH, Bleasel A, Wen L, Eberl S, Byth K, Fulham M, et al. The
topography and significance of extratemporal hypometabolism in refractory
mesial temporal lobe epilepsy examined by FDG-PET. Epilepsia (2010)
51:1365–73. doi: 10.1111/j.1528–1167.2010.02552.x
33. Vinton A, Carne R, Hicks R, Desmond PM, Kilpatrick C, Kaye AH, et al.
The extent of resection of FDG-PET hypometabolism relates to outcome of
temporal lobectomy. Brain (2007) 130:548–60. doi: 10.1093/brain/awl232
34. Koutroumanidis M, Hennessy MJ, Seed PT, Elwes RD, Jarosz J, Morris
RG, et al. Significance of interictal bilateral temporal hypometabolism in
temporal lobe epilepsy. Neurology (2000) 54:1811–21. doi: 10.1212/WNL.54.
9.1811
35. Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al.
Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies.
Seizure (2015) 30:57–63. doi: 10.1016/j.seizure.2015.05.017
36. Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak
M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy
associated with neuronal antibodies. Epilepsy Res. (2017) 129:101–5.
doi: 10.1016/j.eplepsyres.2016.12.010
37. Falip M, Rodriguez-Bel L, Castañer S, Miro J, Jaraba S, Mora J, et al.
Musicogenic reflex seizures in epilepsy with glutamic acid decarbocylase
antibodies. Acta Neurol Scan (2018) 137:272–6. doi: 10.1111/ane.12799
38. Fredriksen JR, Carr CM, Koeller KK, Verdoorn JT, Gadoth A,
Pittock SJ, Kotsenas AL. MRI findings in glutamic acid decarboxylase
associated autoimmune epilepsy. Neuroradiology (2018) 60:239–45.
doi: 10.1007/s00234-018-1976-6
39. Glover R, DeNiro LV, Lasala PA, Weidenheim KM, Graber JJ, Boro
A. ILAE type 3 hippocampal sclerosis in patients with anti-GAD-
related epilepsy. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e122.
doi: 10.1212/NXI.0000000000000122
40. Blümcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi
A, et al. International consensus classification of hippocampal sclerosis in
temporal lobe epilepsy: a Task Force report from the ILAE Commission on
Diagnostic Methods. Epilepsia (2013) 54:1315–29. doi: 10.1111/epi.12220
41. Takagi M, Ishigaki Y, Uno K, Sawada S, Imai J, Kaneko K, et al.
Cognitive dysfunction associated with anti-glutamic acid decarboxylase
autoimmunity: a case-control study. BMC Neurol. (2013) 13:76.
doi: 10.1186/1471-2377-13-76
42. Xie CH, Bai F, Yu H, Shi Y, Yuan Y, Chen G, et al. Abnormal
insula functional network is associated with episodic memory decline
in amnestic mild cognitive impairment. Neuroimage (2012) 63:320–7.
doi: 10.1016/j.neuroimage.2012.06.062
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Falip, Rodriguez-Bel, Castañer, Sala-Padró, Miro, Jaraba,
Casasnovas, Morandeira, Berdejo and Carreño. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neurology | www.frontiersin.org 12 January 2019 | Volume 9 | Article 1143
